{
    "title": "Bristol Myers sees slight 2022 sales growth due to sharply lower Revlimid sales",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10386501/Bristol-Myers-sees-slight-2022-sales-growth-sharply-lower-Revlimid-sales.html",
    "date": "2022-01-10",
    "keywords": [
        "drug",
        "year",
        "company",
        "growth",
        "decade",
        "erman",
        "presentation",
        "cancer",
        "boerner",
        "eliquis",
        "jan",
        "co",
        "revlimid",
        "begin",
        "jp",
        "conference",
        "analyst",
        "refinitiv",
        "average",
        "officer",
        "chris",
        "immunotherapy",
        "blood",
        "thinner",
        "business",
        "doubledigit",
        "decline",
        "loss",
        "exclusivity",
        "blockbuster",
        "part",
        "acquisition",
        "celgene",
        "patent",
        "protection",
        "opdivos",
        "range",
        "share",
        "bristol",
        "revenue",
        "end",
        "approval",
        "place",
        "half",
        "reporting",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}